Researchers at H. Lee Moffitt Cancer Center and Research Institute in Florida, and the University of Connecticut have published a study that suggests marijuana use may be linked to lower prostate cancer prevalence.

Utilizing data from the National Survey on Drug Use and Health spanning 2002 to 2020, the study involved a significant sample size of 2,503 participants across the United States. The participants were categorized based on their marijuana use status: current users, former users, and those who have never used. The researchers also incorporated eleven demographic variables as covariates to ensure the accuracy of their findings.
Researchers found that prostate cancer prevalence was notably lower in current marijuana users (31.7%) and former users (31.6%) compared to those who have never used marijuana (39.9%). This difference was statistically significant, suggesting a protective effect of marijuana against prostate cancer. Further analysis revealed that this trend was particularly pronounced among the elderly (aged 65 and above) and non-Hispanic whites, with current and former users showing significantly lower rates of prostate cancer compared to non-users in these groups.
Continue reading




The Drug Enforcement Administration (DEA) has taken a significant step by proposing to reclassify marijuana from a Schedule I to a Schedule III substance under the federal Controlled Substances Act, established in 1970. This proposal was officially published in the Federal Register on May 21, initiating a 60-day public comment period. If approved, this reclassification will bring notable changes and implications.


Louisiana’s full legislature has voted to pass House Bill 165, sending it to Governor Jeff Landry. The bill received final approval by the House of Representatives today by a vote of 69 to 24. It passed the Senate on May 21 by a vote of 24 to 14.


